Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 3-Month pill course stop latent TB in its tracks?

NCT ID NCT07811518

Prevention Sponsor: Affiliated Hospital of Nantong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are studying whether short-course preventive treatment protects high school and college freshmen with strongly positive TB skin tests from developing active tuberculosis. About 3,000 students across 26 schools in Meishan City, Sichuan Province, China, take either a 3-month regimen of isoniazid plus rifampin or rifapentine, or receive routine health observation without medication. The study tracks participants for 3 to 4 years to see who develops active TB and to check the treatment's safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
short-course tuberculosis preventive treatment with isoniazid plus rifampin or rifapentine
What this could lead to
If it works, schools could adopt short-course preventive treatment as a practical way to stop latent TB from becoming active in teenagers and young adults.
What could go wrong
Students choose their own treatment, so the groups may differ in ways that skew the comparison. Preventive treatment can cause liver problems, and some students may not finish the full course.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 24 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Matriculating freshmen aged 14-24 years enrolled across 26 participating educational institutions * Completion of baseline tuberculosis screening, including systematic symptom screening, digital chest radiography, and tuberculin skin test (TST) * Target cohort requirement: TST strong reactivity (induration ≥15 mm or severe local reactions such as blisters, necrosis, or lymphangitis) with active TB ruled out at baseline * Control cohort requirement: TST induration \<15 mm (including negative \<5 mm, weakly positive 5-9 mm, and moderately positive 10-14 mm) Exclusion Criteria: * Presence of active TB at baseline screening * Voluntary receipt of Vaccae vaccination (for the target cohort)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Latent tuberculosis infection (LTBI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection tuberculosis active tuberculosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Latent tuberculosis infection (LTBI) Tuberculosis (TB)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Nantong University

    RECRUITING

    Nantong, Jiangsu, 226001, China

  • Meishan Municipal Center for Disease Prevention and Control

    RECRUITING

    Meishan, Sichuan, 620010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.